CPT code 87530 represents a molecular laboratory test that uses a nucleic acid probe to detect and quantify Herpes simplex virus (HSV) infection. This diagnostic assay is clinically important for confirming HSV-related lesions and guiding infection control and clinical management decisions. At a national level, molecular HSV testing supports outpatient and inpatient diagnostic workflows and public health surveillance for a common viral pathogen that causes mucocutaneous vesicular lesions.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 87530 denotes, the typical clinical and laboratory settings where it is performed, and which major payers underwrite coverage for molecular HSV testing. The publication also summarizes expected benchmarking topics such as utilization patterns, reimbursement considerations, and relevant coding context. Clinical context provided explains when nucleic acid probe testing for HSV is ordered and how it fits into diagnostic pathways for patients presenting with characteristic blisters or vesicles.

Where specific data elements were not provided in the input, those fields are noted as unavailable. The content is presented for a national audience and focuses on code meaning, clinical relevance, payer scope, and the types of benchmarking and policy information a reader can expect to find in the full publication.